Press Releases

InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital

Published: June 27, 2017

CAMBRIDGE, Mass. (June 27, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Thomas Jefferson University Hospital in Philadelphia, PA. James Harrop, M.D., Professor of Neurological and Orthopedic Surgery, Co-Director at the Delaware Valley Spinal Cord Injury Center, and Principal Investigator at the site, and Josh Heller, M.D., successfully performed the surgery and implantation approximately 22 hours after the injury occurred.   Dr. Harrop […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Allegheny General Hospital

Published: June 20, 2017

CAMBRIDGE, Mass. (June 20, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Allegheny General Hospital in Pittsburgh, PA, part of the Allegheny Health Network (AHN). Drs. Dan Altman, Nestor Tomycz, and Terrence Julien successfully performed the surgery and implantation approximately 21 hours after the injury occurred. Dr. Julien, System Co-Director of Minimally Invasive Spine Surgery and Principal Investigator, said, “We are all hoping […]

View Article
InVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference

Published: June 12, 2017

–   Updated Presentation Time Announced – CAMBRIDGE, Mass. (June 15, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the JMP Securities Annual Life Sciences Conference on Tuesday, June 20, 2017 at 2:30 PM ET at the St. Regis New York in New York City. This is the first time that the company has been invited to present at the JMP Securities Annual Life Sciences Conference.  The conference will include company executives, KOLs, physicians, patients and industry experts discussing a variety of healthcare topics. Mr. Perrin’s presentation will highlight […]

View Article
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting

Published: June 1, 2017

CAMBRIDGE, Mass. (June 1, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the posting of the management presentation and Q&A session recording from the 2017 Annual Shareholders Meeting held on May 30th, 2017. The recording is available on the investor relations page of InVivo’s website at https://www.invivotherapeutics.com/investor-relations/annual-meeting/. Mark Perrin, Chief Executive Officer and Chairman, said, “I was pleased with the turnout at this year’s annual shareholders meeting. The meeting was a great opportunity for me to answer questions directly from our shareholders while providing some key updates on our recent progress.  I look forward to continued opportunities to communicate with […]

View Article
InVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”)

Published: May 30, 2017

– Study to Include Reeve Foundation North American Clinical Trials Network (NACTN) Registry – CAMBRIDGE, Mass. (May 30, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI Registry Study (now called the “CONTEMPO Registry Study”), a complement to the ongoing INSPIRE study of the Neuro-Spinal Scaffold™. The CONTEMPO Registry Study is intended to provide comprehensive natural history benchmarks for INSPIRE study results that include spinal cord injury (SCI) patients with similar baseline characteristics treated since 2006. The NACTN registry is derived from […]

View Article
InVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting

Published: May 9, 2017

CAMBRIDGE, Mass. (May 9, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President, Clinical Operations, will present at the Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting on Saturday, May 13, 2017 at 2:40 PM ET at the Marriott Eaton Center in Toronto, Ontario. Ms. Neff will present an abstract titled “Interim Clinical Results from the Ongoing INSPIRE Pivotal Study to Assess the Safety and Probable Benefit of the Investigational Neuro-Spinal Scaffold for Treatment of Acute Thoracic AIS A Spinal Cord Injury.” Mark Perrin, Chairman and CEO, said, “The Canadian Spinal Cord […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University

Published: May 8, 2017

CAMBRIDGE, Mass. (May 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study  (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Jason J. Chang, M.D., Assistant Professor of Neurological Surgery and co-study investigator, performed the surgery and implantation approximately 77 hours after the injury occurred. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We were pleased to hear that the procedure was a […]

View Article
InVivo Therapeutics Provides Clinical Update and Reports 2017 First Quarter Financial Results

Published: May 4, 2017

– INSPIRE Patient Updates – CAMBRIDGE, Mass. (May 4, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a clinical update, an update on patients in the INSPIRE study of the Neuro-Spinal Scaffold™, and reported financial results for the quarter ended March 31, 2017. Clinical/Regulatory Update Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the first quarter, we continued to make significant progress at InVivo and with the INSPIRE study. By early April, we had enrolled four new patients into the INSPIRE study, with three patients enrolled within 30 days of each other. We also announced four new […]

View Article
InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting

Published: April 20, 2017

CAMBRIDGE, Mass. (Apr 20, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving two oral presentations at the 2017 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and Scientific Support, will present a clinical trial update during the “Clinical Trials 360-degree” session sponsored by Spinal Cord Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr. Aimetti will also present an abstract entitled “Relationship of ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization Costs in Thoracic Spinal Cord […]

View Article
InVivo Therapeutics Announces New Site for INSPIRE Study

Published: April 10, 2017

CAMBRIDGE, Mass. (Apr 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Brigham and Women’s Hospital (BWH) in Boston, MA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. BWH is a teaching hospital of Harvard Medical School and hosts one of the largest neurosurgical intensive care units in the country. “Patients who suffer spinal cord injury face limited options for treatment.  I’m hopeful that spinal cord research, particularly in the area […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.